Heart disease is the leading cause of death in women. Most women who die from it had a 'normal' LDL. The standard lipid panel was designed and validated on male populations in the 1960s - and it systematically underestimates risk in women, particularly during and after the menopause transition.
ApoB, Lipoprotein(a), and hs-CRP are the three markers that have the strongest evidence for reclassifying cardiovascular risk in women. None of them are on a standard lipid panel. All three require a specific order - and the conversation to ask for them.
Why LDL-C isn't enough
LDL-cholesterol measures the cholesterol content carried inside LDL particles. ApoB measures the number of particles themselves - one ApoB protein per atherogenic particle. Two women can have identical LDL-C but very different particle counts: one with large, buoyant particles (lower risk), one with small, dense particles (higher risk). ApoB sees the difference. LDL-C doesn't.
The ACC/AHA now endorse ApoB as a preferred risk marker and a secondary treatment target. For women, particularly those who are insulin resistant or have high triglycerides with borderline LDL, ApoB provides information that changes clinical decisions.
Lipoprotein(a): the genetic wild card
Lp(a) is structurally similar to LDL but carries an additional protein - apolipoprotein(a) - that makes it particularly atherogenic and thrombogenic. Approximately one in five people carry elevated Lp(a) (above 50 mg/dL or 125 nmol/L), and this is almost entirely genetically determined. Diet and statins do not meaningfully lower it.
Elevated Lp(a) roughly doubles the risk of coronary artery disease and aortic stenosis, independently of other risk factors. Because it's genetic and stable over a lifetime, you only need to test it once. But most people have never heard of it and have never had it checked.
hs-CRP: vascular inflammation
High-sensitivity CRP measures low-grade systemic inflammation - the kind that predicts cardiovascular events over years, not the kind elevated by an acute infection. Persistent hs-CRP above 2 mg/L roughly doubles cardiovascular risk independently of lipids. In the landmark JUPITER trial, 17,000 participants with normal LDL but elevated hs-CRP reduced major cardiovascular events by 44% with statin therapy.
In women, hs-CRP is a stronger predictor of cardiovascular events than LDL-C. The Women's Health Study demonstrated this clearly: hs-CRP outperformed LDL-C, total cholesterol, and homocysteine for predicting first cardiovascular events in a cohort of nearly 28,000 women.
When menopause changes everything
Estrogen is cardioprotective. It raises HDL, lowers LDL and ApoB, keeps arterial walls flexible, and suppresses vascular inflammation. As estrogen withdraws through perimenopause, the lipid profile often shifts substantially - sometimes within a single year. ApoB and LDL-C rise; HDL may fall; hs-CRP climbs alongside visceral fat.
The window of highest change - and the highest opportunity for preventive intervention - is the early transition. Baselining ApoB, Lp(a), and hs-CRP in the early 40s, before the inflection, allows you to track the trajectory rather than reacting to it a decade later.